Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
M.M. Herenius¹, A.S.F. Oliveira¹, C.A. Wijbrandts¹, D. Gerlag¹, Paul P. Tak² and Maria C. Lebre³, ¹Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…
Abstract Number: 490 • 2012 ACR/ARHP Annual Meeting
12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Douglas E. Schlichting², Kimberly L. Sterling³, Edward Keystone⁴, Peter Taylor⁵, Mark C. Genovese⁶, Louise Johnson⁷, Juan C. Rizo Rodriguez⁸, Chin H. Lee² and Carol L. Gaich³, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada, ⁵Kennedy Institute of Rheumatology, London, United Kingdom, ⁶Division of Rheumatology, Stanford University, Palo Alto, CA, ⁷PharmaNet/i3, Eden Prairie, MN, ⁸Clinical Investigation, Centro de Alta Especialidad en Reumatología e Investigación del Potosí, San Luis Potosi, San Luis Potosi, Mexico
Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the…
Abstract Number: 345 • 2012 ACR/ARHP Annual Meeting
Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis – Validation in a Murine Collagen Induced Arthritis Model
Gurkirpal Singh¹, Robinson Vidva², Prashant Nair², Saumya Radhakrishnan², Pradeep Fernandes², Taher Abbasi², Canio Refino³, Jay Dela Cruz³ and Shireen Vali², ¹Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, ²CellWorks Group, Saratoga, CA, ³InTouch Bio, Alameda, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves complex interactions of multiple cell systems, cytokines and mediators, and interlinked signaling. While molecularly-targeted therapies manipulate specific interactions, it is…
Abstract Number: 2101 • 2012 ACR/ARHP Annual Meeting
How Much Can Patient Reported Outcomes Improve Among Rheumatoid Arthritis Patients Who Have a Clinical Response to Biologic Therapy but Have Not Attained Low Disease Activity?
Jeffrey R. Curtis¹, Ying Shan, Jie Zhang¹, Jeffrey D. Greenberg³ and George W. Reed⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²New York Hospital for Joint Disease, New York, NY, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Current treat-to-target (T2T) recommendations suggest that rheumatoid arthritis (RA) patients should strive for remission or low disease activity (LDA) as a goal. Treatment changes…
Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Lillian J. Barra¹, Andrew Ha², Louise Sun³, Catarina Fonseca⁴ and Janet E. Pope⁵, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²The University of Toronto, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Universidade de Lisboa, Lisbon, Portugal, ⁵Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…
Abstract Number: 494 • 2012 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
William Bensen¹, Denis Choquette², Isabelle Fortin³, Alice V. Klinkhoff⁴, Susan M. Otawa⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴The Mary Pack Arthritis Ctr, Vancouver, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men depending on age. Furthermore, in women RA incidence increases…
Abstract Number: 195 • 2012 ACR/ARHP Annual Meeting
Inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study
Arsene Mekinian¹, Olivier Decaux², Geraldine Falgarone³, Thorsten Braun Sr.⁴, Eric Toussirot⁵, Loic Raffray⁶, Bruno Gombert⁷, Bruno de Wazieres⁸, Anne Laure Buchdaul⁹, Jean-Marc Ziza¹⁰, David Launay¹¹, Guillaume Denis¹², Serge Madaule¹³, Pierre Fenaux¹⁴ and Olivier Fain¹⁵, ¹Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ²Department of Internal Medicine, Rennes University Hospital, Rennes, France, ³Rheumatology, Hopital avicenne, Paris, France, ⁴Hematology, Avicenne hospital, Bobigny, France, ⁵Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁶Internal Medicine, CHU de Bordeaux, Bordeaux, France, ⁷Internal Medicine, La Rochelle hospital, La Rochelle, France, ⁸Internal Medecine, CHU de Nimes, Nimes, France, ⁹Internal Medicine, Douai hospital, Douai, France, ¹⁰Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹¹Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Internal Medicine, Rochefoucault hospital, Rochefoucault, France, ¹³Rheuamtology, Albi hospital, Albi, France, ¹⁴Hematology, Avicenne Hospital, France, ¹⁵Internal Medicine, Jean Verdier Hospital, Bondy, France
Inflammatory arthritis in patients with myelodysplastic syndrome: French multicenter retrospective study.For the Société Nationale Française de Médecine Interne (SNFMI), the CRI (Club Rhumatismes Inflammation) and…
Abstract Number: 2107 • 2012 ACR/ARHP Annual Meeting
Assessing Subclinical Synovitis in Rheumatoid Arthritis: Arthrosonographic Findings in Patients with Good Response to Therapy
Matthias Witt¹, Felix Mueller², Axel Nigg², Christiane Reindl³, Hendrik Schulze-Koops² and Mathias Grunke², ¹Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ³Division for Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany
Background/Purpose: Treat-to-target is a key principle in rheumatoid arthritis. Composite scores such as the DAS-28 help to monitor disease activity and response to therapy. However,…
Abstract Number: 1310 • 2012 ACR/ARHP Annual Meeting
Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF
Raphaèle Seror¹, Houria Chavez², anne-Aurélie Mazet³, Jeremie Sellam⁴, Bruno Fautrel⁵, Maxime Dougados⁶, Yassine Taoufik² and Xavier Mariette⁷, ¹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Virology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁴Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Some cases of progressive multifocal leukoencephalopathy (PML) have been described in patients with autoimmune diseases with profound immunosuppression, due to replication of JC polyomavirus…
Abstract Number: 502 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
Elena Becerra¹, Geraldine Cambridge² and Maria J. Leandro², ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Lung involvement is common in patients with Rheumatoid Arthritis (RA), including interstitial lung disease (ILD), pleural disease and small airway disease. There are no…
Abstract Number: 110 • 2012 ACR/ARHP Annual Meeting
Comparing Palmar and Dorsal Ultrasound Assessment of Small Joint Synovitis in Rheumatoid Arthritis: Dorsal Greyscale Mode Yields Significantly Better Concordance with Power Doppler
Matthias Witt¹, Felix Mueller¹, Hendrik Schulze-Koops² and Mathias Grunke³, ¹Division of Rheumatology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Division of Rheumatology, University of Munich, Munich, Germany, ³Division for Rheumatology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
Background/Purpose: MCP and PIP joints are frequently involved in rheumatoid arthritis. Complete ultrasound assessment of these joints requires the palmar and the dorsal approach for…
Abstract Number: 2098 • 2012 ACR/ARHP Annual Meeting
Patient Report Outcomes Variance Between Centers Is Much Lower Than Physician and Laboratory Assessed Measures of Rheumatoid Arthritis Activity: Results From a Multinational Study
Nasim A. Khan¹, Horace Spencer², Tuulikki Sokka³ and QUEST-RA⁴, ¹Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Jyväskylä
Background/Purpose: Clinical trials and epidemiological rheumatoid arthritis (RA) studies often recruit patients from multiple centers. We studied the proportion of variance in the American…
Abstract Number: 1288 • 2012 ACR/ARHP Annual Meeting
A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice
Jose Inciarte-Mundo¹, Maria Victoria Hernández², Violeta Rosario¹, Sonia Cabrera¹, Virginia Ruiz-Esquide³, Maria Eugenia Gomez-Caballero¹, Jose A. Gómez-Puerta¹, Julio Ramirez¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Biological agents are used to treat chronic arthritis according to the standard dosages from phase III clinical trials. However, in some patients, a good…
Abstract Number: 479 • 2012 ACR/ARHP Annual Meeting
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Patrick Durez¹, Pedro Miranda², Antoaneta Toncheva³, Alberto Berman Sr.⁴, Oscar L. Rillo⁵, Yves Boutsen⁶, Tatjana Kehler⁷, Eugenia Mociran⁸, LiAn Soto Saez⁹, Bruno Fautrel¹⁰, Xavier Mariette¹¹, Panayot Solakov¹², Eleonora Lucero¹³, Tonko Vlak¹⁴, Simeon Grazio¹⁵, Ksenija Mastrovic¹⁶, Rodica Chiriac¹⁷, Géraldine Grouard-Vogel¹⁸, Olivier Dhellin¹⁸, Stéphane Ouary¹⁸, Pierre Vandepapeliere¹⁸ and Marie-Christophe Boissier¹⁹, ¹Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ²Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ³National Multiprofile Transport Hospital, Sofia, Bulgaria, ⁴Internal Medicine, Hospital Padilla, Tucuman, Argentina, ⁵Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁶UCL Mont-Godinne, Godinne, Belgium, ⁷Thalassotherapia Opatija, Opatija, Croatia, ⁸Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ⁹Sociedad Medica del Aparato Locomotor SA, Santiago de Chile, Chile, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹²Plovdiv, Diagnostic and Consulting Center, Plovdiv, Bulgaria, ¹³Rheumatology Unit, Padilla Hospital, Tucumán, Argentina, ¹⁴University Hospital Split, Split, Croatia, ¹⁵Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ¹⁶Clinical Hospital Sveti Duh, Zagreb, Croatia, ¹⁷Rehabilitation clinical Hospital Iasi, Iasi, Romania, ¹⁸NEOVACS SA, Paris, France, ¹⁹Dept of Rheumatology, Hopital Avicenne, Bobigny, France
Background/Purpose: Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been successful in the treatment of rheumatoid arthritis. However secondary resistances are frequent and impose…
Abstract Number: 112 • 2012 ACR/ARHP Annual Meeting
Time-Integrated Synovitis Activity Assessed by Power Doppler Ultrasound Significantly Correlates with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Methotrexate Alone but Not in Those Treated with TNF Antagonists
Kei Ikeda, Daiki Nakagomi, Yoshie Sanayama, Mieko Yamagata, Ayako Okubo, Taro Iwamoto, Hirotoshi Kawashima, Kentaro Takahashi and Hiroshi Nakajima, Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan
Background/Purpose: Although a number of studies have shown a higher sensitivity of ultrasound than clinical joint examination in detecting synovitis in patients with rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].